Affiliations: Texas Tech University Health Sciences Center,
University of Texas Southwestern Medical Center, Dallas, TX
Correspondence to: Ronald G. Hall II, PharmD, Texas Tech University Health Sciences Center, School of Pharmacy, 4500 Lancaster, Building 7, R 119A, Dallas, TX 75216; e-mail: email@example.com
We read the study by Jeffres and colleagues1 (October 2006) with interest and were intrigued with the conclusion that trough concentrations > 15 μg/mL may not offer any advantage over traditional targets. This retrospective study was not adequately powered to detect differences between traditional and aggressive trough concentrations. Therefore, a statistically insignificant result is only inconclusive and not a negative finding.
With substantial imbalances between nonsurvivors and survivors, assessments of the variable in question in both analyses are impossible. Nonsurvivors were older with higher APACHE (acute physiology and chronic health evaluation)-II scores and had greater frequencies of bacteremia, end-stage renal disease, mechanical ventilation, and vasopressors. The trough concentration ≥ 15 μg/mL group had higher APACHE-II scores and more patients receiving mechanical ventilation and vasopressors (a factor significantly associated with mortality in the multivariate analysis). Is it plausible that sicker patients receiving trough concentration ≥ 15 μg/mL have the same risk of death as less ill patients receiving lower vancomycin trough concentrations?
The unavailability of minimum inhibitory concentrations made it impossible to calculate the area under the inhibitory curve values, although the accompanying editorial2stated these were calculated. Disk diffusion does not adequately identify Staphylococcus aureus with reduced vancomycin susceptibility.3 While most isolates likely had an minimum inhibitory concentration ≤ 0.5 μg/mL, we will never know for certain. Therefore, pharmacodynamic target attainment rates cannot be compared.
While vancomycin may not display pharmacokinetic qualities of the optimal agent for methicillin-resistant S aureus pneumonia, prospective, randomized trials comparing vancomycin target concentrations will hopefully provide some definitive answers to the role of aggressive vancomycin dosing for this disease. The major issue is that vancomycin has not had a fair comparison. Unfortunately, this study had the worst possible result, as it did not definitively conclude anything.1 However, this study and the accompanying editorial suggest that the time for optimizing vancomycin dosing is over and clinicians should use “better” agents.
Dr. Hall is a member of the Speaker’s Bureau for Wyeth. Ms. Adams-Huet has no conflicts of interest to disclose.
Become a CHEST member and receive a FREE subscription as a benefit of membership.
Individuals can purchase this article on ScienceDirect.
Individuals can purchase a subscription to the journal.
Individuals can purchase a subscription to the journal or buy individual articles.
Learn more about membership or Purchase a Full Subscription.
Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited:
Customize your page view by dragging & repositioning the boxes below.
Enter your username and email address. We'll send you a reminder to the email address on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.